Inhibidor del receptor de la interleucina-6 en el tratamiento de la artritis reumatoide: seguridad y dosificación del tocilizumab

Melania Martínez-Morillo, Dolors Grados, Beatriz Tejera, Alejandro Olivé Marqués
{"title":"Inhibidor del receptor de la interleucina-6 en el tratamiento de la artritis reumatoide: seguridad y dosificación del tocilizumab","authors":"Melania Martínez-Morillo,&nbsp;Dolors Grados,&nbsp;Beatriz Tejera,&nbsp;Alejandro Olivé Marqués","doi":"10.1016/j.semreu.2011.02.003","DOIUrl":null,"url":null,"abstract":"<div><p>Biological therapies may herald the cure for rheumatoid arthritis. Targeted biologic therapies have changed the outcome of this disease. Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor and has been approved in many countries for the treatment of moderate to severe rheumatoid arthritis. A number of clinical trials have demonstrated the efficacy of tocilizumab in active rheumatoid arthritis. This review summarizes the data on the safety and dosage of this drug.</p></div>","PeriodicalId":101152,"journal":{"name":"Seminarios de la Fundación Espa?ola de Reumatología","volume":"12 2","pages":"Pages 57-60"},"PeriodicalIF":0.0000,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.semreu.2011.02.003","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminarios de la Fundación Espa?ola de Reumatología","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1577356611000273","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Biological therapies may herald the cure for rheumatoid arthritis. Targeted biologic therapies have changed the outcome of this disease. Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor and has been approved in many countries for the treatment of moderate to severe rheumatoid arthritis. A number of clinical trials have demonstrated the efficacy of tocilizumab in active rheumatoid arthritis. This review summarizes the data on the safety and dosage of this drug.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
白介素-6受体抑制剂治疗类风湿关节炎的安全性和剂量
生物疗法可能预示着类风湿关节炎的治愈。靶向生物治疗已经改变了这种疾病的预后。Tocilizumab是一种针对白细胞介素-6受体的人源化单克隆抗体,已在许多国家被批准用于治疗中度至重度类风湿性关节炎。许多临床试验已经证明tocilizumab治疗活动性类风湿关节炎的疗效。本文综述了该药的安全性和剂量方面的资料。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Formación posgrado en Reumatología: perspectiva en Europa Microbiología de la tuberculosis Cerca de la Universidad española Modulación del cambio de isotipo de las inmunoglobulinas por señales del sistema inmunitario innato Síndrome de Cogan
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1